Kezar Life Sciences Entered into a Collaboration and License Agreement with Everest Medicines for Zetomipzomib to Treat Lupus Nephritis
- Kezar will receive an up front, ~$132.5M upon achievement of development, regulatory & commercialization milestones along with royalties on net sales. Both companies collaborate on future clinical trials & indications for the continued development of zetomipzomib
- Everest Medicines to get an exclusive right to develop & commercialize zetomipzomib, a selective immunoproteasome inhibitor in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam & Philippines
- Everest will also collaborate with Kezar for the P-IIb trial (PALIZADE) of zetomipzomib in active LN patients. In the licensed territories, Everest will lead the trial expenditures & will also provide its regional regulatory & trial capabilities for the (PALIZADE) study
Ref: Businesswire | Image: Everest Medicines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.